$1.53 Billion is the total value of Sofinnova Investments, Inc.'s 55 reported holdings in Q2 2023. The portfolio turnover from Q1 2023 to Q2 2023 was 65.4% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| KRTX | Sell | Karuna Therapeutics Inc | $299,502,161 | -7.0% | 1,381,149 | -22.1% | 19.62% | -4.8% |
| NTRA | Natera Inc | $150,873,250 | -12.4% | 3,100,560 | 0.0% | 9.88% | -10.2% | |
| AZN | New | AstraZeneca PLCsponsored adr | $121,491,292 | – | 1,697,517 | +100.0% | 7.96% | – |
| ISRG | Buy | Intuitive Surgical Inc | $68,792,173 | +80.0% | 201,182 | +34.5% | 4.51% | +84.4% |
| ASND | Ascendis Pharma A/Ssponsored adr | $67,297,356 | -16.8% | 754,032 | 0.0% | 4.41% | -14.8% | |
| AVTE | Aerovate Therapeutics Inc | $64,461,465 | -15.0% | 3,758,686 | 0.0% | 4.22% | -12.9% | |
| MRK | Sell | Merck & Co Inc | $60,853,570 | -32.0% | 527,373 | -37.3% | 3.99% | -30.4% |
| VERA | Vera Therapeutics Inccl a | $55,647,854 | +106.8% | 3,467,156 | 0.0% | 3.64% | +111.8% | |
| VRTX | New | Vertex Pharmaceuticals Inc | $51,132,523 | – | 145,300 | +100.0% | 3.35% | – |
| EXEL | Buy | Exelixis Inc | $48,935,703 | +203.3% | 2,560,738 | +208.1% | 3.20% | +210.6% |
| DXCM | Buy | Dexcom Inc | $47,641,227 | +59.4% | 370,720 | +44.1% | 3.12% | +63.3% |
| IDXX | New | IDEXX Laboratories Inc | $35,494,603 | – | 70,674 | +100.0% | 2.32% | – |
| IMTX | Sell | Immatics NV | $35,098,760 | +62.4% | 3,041,487 | -2.9% | 2.30% | +66.4% |
| SNDX | Buy | Syndax Pharmaceuticals Inc | $33,117,351 | +45.8% | 1,582,291 | +47.1% | 2.17% | +49.3% |
| BSX | New | Boston Scientific Corp | $32,933,291 | – | 608,861 | +100.0% | 2.16% | – |
| RETA | Sell | Reata Pharmaceuticals Inccl a | $32,879,143 | -42.4% | 322,471 | -48.6% | 2.15% | -41.0% |
| CYTK | Buy | Cytokinetics Inc | $27,506,097 | +120.9% | 843,228 | +138.3% | 1.80% | +126.4% |
| INBX | Sell | Inhibrx Inc | $25,915,427 | +10.4% | 998,283 | -19.8% | 1.70% | +13.0% |
| ZNTL | Sell | Zentalis Pharmaceuticals Inc | $23,358,021 | -5.6% | 828,005 | -42.5% | 1.53% | -3.3% |
| INZY | Inozyme Pharma Inc | $20,360,066 | -2.8% | 3,655,308 | 0.0% | 1.33% | -0.4% | |
| GERN | Sell | Geron Corp | $17,427,588 | -2.9% | 5,429,155 | -34.4% | 1.14% | -0.6% |
| BAX | New | Baxter Intl Inc | $16,501,832 | – | 362,200 | +100.0% | 1.08% | – |
| IDYA | Buy | IDEAYA Biosciences Inc | $15,621,531 | +151.1% | 664,746 | +46.7% | 1.02% | +157.0% |
| IMGN | Sell | ImmunoGen Inc | $15,611,491 | +339.7% | 827,318 | -10.5% | 1.02% | +350.7% |
| ARGX | New | argenx SEsponsored adr | $15,558,411 | – | 39,921 | +100.0% | 1.02% | – |
| YMAB | Y-mAbs Therapeutics Inc | $14,899,148 | +35.5% | 2,194,278 | 0.0% | 0.98% | +38.8% | |
| RVMD | Buy | Revolution Medicines Inc | $13,920,085 | +249.6% | 520,377 | +183.1% | 0.91% | +257.6% |
| AXSM | Buy | Axsome Therapeutics Inc | $12,880,330 | +72.7% | 179,242 | +48.3% | 0.84% | +76.9% |
| VIR | Sell | Vir Biotechnology Inc | $11,973,510 | -21.7% | 488,117 | -25.8% | 0.78% | -19.9% |
| PTCT | Sell | PTC Therapeutics Inc | $10,592,217 | -57.7% | 260,443 | -49.6% | 0.69% | -56.7% |
| Sell | Marinus Pharmaceuticals Inc | $10,454,042 | +26.2% | 962,619 | -19.8% | 0.68% | +29.2% | |
| GRTX | Galera Therapeutics Inc | $9,621,181 | +21.9% | 3,083,712 | 0.0% | 0.63% | +24.8% | |
| REPL | New | Replimune Group Inc | $8,101,203 | – | 348,889 | +100.0% | 0.53% | – |
| AGEN | Sell | Agenus Inc | $7,854,611 | -19.4% | 4,909,132 | -23.4% | 0.51% | -17.5% |
| VIR | New | Vir Biotechnology Incput | $7,359,000 | – | 300,000 | +100.0% | 0.48% | – |
| CLDX | Sell | Celldex Therapeutics Inc | $6,709,929 | -55.5% | 197,758 | -52.8% | 0.44% | -54.5% |
| DYN | New | Dyne Therapeutics Inc | $4,961,790 | – | 441,048 | +100.0% | 0.32% | – |
| NXTC | Nextcure Inc | $4,809,341 | +21.6% | 2,671,856 | 0.0% | 0.32% | +24.5% | |
| NCNA | Nucana PLCsponsored adr | $4,423,999 | -17.7% | 5,599,999 | 0.0% | 0.29% | -15.7% | |
| BOLT | Bolt Biotherapeutics Inc | $3,525,679 | -7.9% | 2,754,437 | 0.0% | 0.23% | -5.7% | |
| New | Marinus Pharmaceuticals Inccall | $2,172,000 | – | 200,000 | +100.0% | 0.14% | – | |
| Nucana PLC | $1,896,000 | -17.7% | 2,400,000 | 0.0% | 0.12% | -15.6% | ||
| FGEN | New | FibroGen Incput | $1,755,000 | – | 650,000 | +100.0% | 0.12% | – |
| FGEN | New | FibroGen Inc | $1,721,431 | – | 637,567 | +100.0% | 0.11% | – |
| PDSB | PDS Biotechnology Corp | $717,454 | -18.2% | 142,635 | 0.0% | 0.05% | -16.1% | |
| FGEN | New | FibroGen Inccall | $675,000 | – | 250,000 | +100.0% | 0.04% | – |
| FUSN | Fusion Pharmaceuticals Inc | $546,852 | +23.9% | 117,099 | 0.0% | 0.04% | +28.6% | |
| SVRA | New | Savara Inc | $307,512 | – | 96,248 | +100.0% | 0.02% | – |
| ALLK | New | Allakos Inc | $272,347 | – | 62,465 | +100.0% | 0.02% | – |
| SYBX | Synlogic Inc | $247,238 | -32.0% | 574,972 | 0.0% | 0.02% | -30.4% | |
| MIRM | New | Mirum Pharmaceuticals Inc | $235,132 | – | 9,089 | +100.0% | 0.02% | – |
| SPRB | New | Spruce Biosciences Inc | $124,762 | – | 58,029 | +100.0% | 0.01% | – |
| ALNY | Exit | Alnylam Pharmaceuticals Inc | $0 | – | -448 | -100.0% | -0.01% | – |
| BLUE | Exit | bluebird bio Inc | $0 | – | -672,815 | -100.0% | -0.14% | – |
| NVCR | Exit | Novocure Ltdcall | $0 | – | -50,000 | -100.0% | -0.19% | – |
| KROS | Exit | Keros Therapeutics Inc | $0 | – | -77,100 | -100.0% | -0.21% | – |
| IMGN | Exit | ImmunoGen Inccall | $0 | – | -1,000,000 | -100.0% | -0.25% | – |
| KURA | Exit | Kura Oncology Inc | $0 | – | -616,169 | -100.0% | -0.48% | – |
| CTIC | Exit | CTI Biopharma Corp | $0 | – | -2,794,542 | -100.0% | -0.75% | – |
| RXDX | Exit | Prometheus Biosciences Inc | $0 | – | -123,842 | -100.0% | -0.85% | – |
| SRPT | Exit | Sarepta Therapeutics Inc | $0 | – | -119,065 | -100.0% | -1.05% | – |
| ISEE | Exit | IVERIC bio Inc | $0 | – | -905,982 | -100.0% | -1.41% | – |
| KDNY | Exit | Chinook Therapeutics Inc | $0 | – | -1,002,348 | -100.0% | -1.48% | – |
| TVTX | Exit | Travere Therapeutics Inc | $0 | – | -1,263,721 | -100.0% | -1.82% | – |
| BMRN | Exit | Biomarin Pharmaceutical Inc | $0 | – | -359,035 | -100.0% | -2.23% | – |
| BIIB | Exit | Biogen Inc | $0 | – | -132,600 | -100.0% | -2.36% | – |
| HZNP | Exit | Horizon Therapeutics PLC | $0 | – | -408,819 | -100.0% | -2.85% | – |
| LLY | Exit | Eli Lilly and Co | $0 | – | -137,100 | -100.0% | -3.01% | – |
| SPY | Exit | SPDR S&P 500 ETF Trustput | $0 | – | -200,000 | -100.0% | -5.24% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-08-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Natera, Inc. | 23 | Q3 2023 | 20.5% |
| Ascendis Pharma A/S | 23 | Q3 2023 | 27.9% |
| NuCana plc | 23 | Q3 2023 | 15.2% |
| Synlogic Inc. (fmrly Mirna) | 22 | Q2 2023 | 0.9% |
| Y-mAbs Therapeutics, Inc. | 21 | Q3 2023 | 6.5% |
| ObsEva SA | 20 | Q4 2022 | 11.0% |
| Nucana PLC | 19 | Q3 2023 | 9.7% |
| SYNDAX PHARMACEUTICALS INC | 19 | Q3 2023 | 2.2% |
| PDS Biotechnology Corporation | 19 | Q3 2023 | 0.1% |
| Karuna Therapeutics, Inc. | 18 | Q3 2023 | 27.1% |
View Sofinnova Investments, Inc.'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| OTONOMY, INC.Sold out | February 14, 2022 | 0 | 0.0% |
View Sofinnova Investments, Inc.'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-13 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-11 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-08 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-02-14 |
| SC 13G/A | 2022-02-14 |
View Sofinnova Investments, Inc.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.